AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 282 min read$LH

Labcorp forecasts 2026 adjusted EPS $18.30-$18.70 while estimating 2027 PAMA impact at $125M (NYSE:LH)

Labcorp reported Q3 2026 revenue growth of 7% and EPS growth of 14.5%. The company forecasted 2026 adjusted EPS of $18.30-$18.70 and estimated a $125M impact from PAMA in 2027. CEO Adam Schechter highlighted strong quarterly performance.

Original reporting
seekingalpha.com
Published Oct 28, 2026, 6:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 6:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$LH
Bullish
high confidence
Mentioned
$LH
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$LHBullishHigh
01

Why it matters

Strong guidance may trigger a rally in LH and related health‑services stocks.

02

Market read

First report of FY 2026 EPS guidance for a large‑cap health‑services firm.

03

What to watch

Potential regulatory or reimbursement risks could offset earnings upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Labcorp's earnings call highlighted 7% revenue growth and margin expansion.

Company-level read

Ticker impact

$LHBullishHigh confidence
Context

Labcorp issued FY 2026 adjusted EPS guidance of $18.30‑$18.70 and forecast a $125M PAMA impact for 2027.

Expected impact

upside as investors price in stronger earnings outlook

Evidence & confidence

The EPS range and sizable PAMA cost reduction are material for a large-cap health‑services firm.

Market effects

Sector

May lift broader health‑services and diagnostics sector expectations.

Regional

Positive for U.S. equities, especially large‑cap biotech and lab services.

Global

Limited to investors tracking U.S. healthcare earnings trends.

Counterpoint

What could challenge this read

If guidance already priced in, upside could be muted.

Key entities

  • company
    Labcorp

    U.S. clinical laboratory services provider.

Read at source← All news

StoryLabcorp posts Q3 2026 revenue and adjusted EPS growth and lifts full‑year guidance

Also covered by

5 outlets

Related articles

OCT 28
$LHHighAI 8/10

Labcorp (LH) Q3 2026 Earnings Call Transcript

LabCorp (LH) reported Q3 2026 revenue growth of 7% to $3.8B, EPS growth of 14.5% to $4.78, and raised 2026 guidance. The company expressed concerns over proposed PAMA fee schedule changes, which may reduce Medicare reimbursement rates. LabCorp highlighted growth in diagnostics and biopharma services, FDA approvals, and strategic acquisitions, including MLM Medical Labs and agreements with Myriad Genetics and Millennium Health.

finance.yahoo.com3 min
OCT 28
$LHMedAI 8/10

Labcorp Holdings Inc. Q3 2026 Earnings Call Summary

Labcorp reported 7% revenue growth in Q3 2026, driven by diagnostics and biopharma. Enterprise margin expanded by 60 basis points. The company raised full-year guidance despite $10M in foreign currency headwinds. Management expects a $125M impact from PAMA in 2027. Recent acquisitions and the Launchpad initiative aim to offset reimbursement pressures. Biopharma growth is expected to be high-single-digit, supported by an $8.9B backlog.

finance.yahoo.com3 min
OCT 28
$LHHighAI 9/10

Labcorp (LH) stock trades up, here is why

Labcorp (LH) shares rose 10.3% after reporting Q3 revenue of $3.81B, beating estimates, and raising its full-year 2026 outlook to 5.9-6.7% revenue growth and $18.30-$18.70 adjusted EPS. The company's stock has gained 45.4% year-to-date, reaching a 52-week high of $365.79.

stockstory.org2 min
OCT 28
$LHHighAI 8/10

Labcorp Q3 Earnings Call Highlights

Labcorp reported Q3 revenue growth of 8.5% in biopharma services, with central lab services up 11.3%. Adjusted operating income rose to $159M. The company raised 2026 revenue and EPS guidance, citing strong organic performance. Labcorp also addressed PAMA-related reimbursement pressures expected in 2027 and announced several acquisitions.

finance.yahoo.com2 min
OCT 28
$WENMed

Stocks making the biggest moves midday: Wendy's, Wingstop, F5, Enphase Energy, Labcorp & more

Wendy's rose 15% on a $1.4B privatization proposal from Trian Fund. Brinker International and Wingstop gained 15% after raising guidance and beating earnings. F5 dropped 19% on weak guidance and a downgrade. Labcorp and GE HealthCare advanced on raised guidance. Ultralife surged 145% on a $320M acquisition deal. Enphase Energy fell 16% on missed revenue. PPG Industries rose 6% on earnings beat and raised guidance. Robinhood fell 2% on missed profit. SK hynix advanced 11% on strong earnings.

cnbc.com3 min